个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Wang, S.[1] * ; Hong, R.[2] ; Xu, F.[3] ; Xia, W.[4] ; Teng, Y.[5] ; Ouyang, Q.[6] ; Yuan, Z.[2] ; Jiang, K.[2] ; Lin, Y.[7] ; Liu, X.[8] ; Chen, Q.[9] ; Wu, X.[10] ; Shi, Y.[2] ; Huang, J.[2] ; An, X.[2] ; Xue, C.[2] ; Bi, X.[2] ; Zheng, Q.[2] ; Chen, M.[2] ; Li, H.[12] ;
机构： [1]Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou,China [3]Medical Oncology Department, Sun Yat-sen University Cancer Center,Guangzhou, Guangdong, China [4]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guang Dong, China [5]Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China [6]Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha,China [7]Department of Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China [8]Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China [9]Department of Breast, Guangdong Provincial Chinese Medicine Hospital, Guangzhou, China [10]Department of Breast,Hubei Cancer Hospital, Wuhan, China [11]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China [12]Department of Breast Surgery, Sichuan Cancer Hospital, Chengdu, China
出处：
DOI： 10.1016/j.annonc.2024.08.319
ISSN：
基金：
Sun Yat-sen University
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
推荐引用方式(GB/T 7714)：
Wang S.,Hong R.,Xu F.,et al.Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial[J].ANNALS OF ONCOLOGY.2024,35:S374-S374.doi:10.1016/j.annonc.2024.08.319.
APA：
Wang, S.,Hong, R.,Xu, F.,Xia, W.,Teng, Y....&Li, H..(2024).Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial.ANNALS OF ONCOLOGY,35,
MLA：
Wang, S.,et al."Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial".ANNALS OF ONCOLOGY 35.(2024):S374-S374

资源点击量：59140 今日访问量：2 总访问量：4853 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号